Financial news, mergers and acquisitions, partnerships, and alliances.
BD alleges Cytek hired away former BD employees to develop flow cytometry products to compete against BD.
The company reported that it signed agreements for 337 instruments , while revenue-generating placements totaled 78 across the US, European, and Middle East regions.
The investment bank gave the company's stock an Outperform rating with a target price of $90 per share.
The company offers a range of tumor profiling products including the OncoDeep solid tumor test and the OncoTrace liquid biopsy test.
Genetic Technologies and Blockchain Global may partner to develop medical and biotechnology applications that combine their respective technologies.